Long-term (LT) Exposure to low-dose prednisone given with or without abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients

被引：0
|
作者：
Ryan, Charles J. [1 ]
Chi, Kim N. [2 ]
de Bono, Johann S. [3 ,4 ]
Fizazi, Karim [5 ]
Gomella, Leonard G. [6 ,7 ]
Miller, Kurt [10 ]
Rathkopf, Dana E. [8 ,9 ,11 ]
Scher, Howard I. [6 ,7 ]
Shore, Neal D. [10 ]
De Porre, Peter [8 ,9 ,11 ]
Londhe, Anil [8 ,9 ,11 ]
McGowan, Tracy [12 ]
Pelhivanov, Nonko [8 ,9 ,11 ]
Charnas, Robert [8 ,9 ,11 ]
Todd, Mary B. [13 ]
Montgomery, Bruce [14 ]
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] BC Canc Agcy, Vancouver, BC, Canada
[3] Inst Canc Res, London, England
[4] Univ Paris 11, Inst Gustave Roussy, Paris, France
[5] Univ Paris 11, Inst Gustave Roussy, Paris, France
[6] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA USA
[7] Charite Univ Med Berlin, Berlin, Germany
[8] Mem Sloan Kettering Canc Ctr, New York, NY USA
[9] Weill Cornell Med Coll, New York, NY USA
[10] Atlantic Urol Clin, Carolina Urol Res Ctr, Panama City, Panama
[11] Janssen Res & Dev, London, England
[12] Janssen Sci Affairs, London, England
[13] Janssen Global Serv, Titusville, NJ USA
[14] Univ Washington, Seattle, WA 98195 USA
来源：
BJU INTERNATIONAL | 2015年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
118
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [41] Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC) and prior therapy with ketoconazole: A Prostate Cancer Clinical Trials Consortium study.
    Ryan, C. J.
    Harzstark, A. L.
    Lin, A. M.
    Fong, L.
    Grycz, K.
    Szmulewitz, R. Z.
    Weinberg, V. K.
    Molina, A.
    Small, E. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).
    Cavaliere, Carla
    Caffo, Orazio
    Ortega, Cinzia
    D'aniello, Carmine
    Di Napoli, Marilena
    Cecere, Sabrina Chiara
    Della Pepa, Chiara
    Crispo, Anna
    Maines, Francesca
    Ruatta, Fiorella
    Iovane, Gelsomina
    Montella, Maurizio
    Pignata, Sandro
    Facchini, Gaetano
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer
    K. N. Chi
    A. Tolcher
    P. Lee
    P. J. Rosen
    C. K. Kollmannsberger
    K. P. Papadopoulos
    A. Patnaik
    A. Molina
    J. Jiao
    C. Pankras
    B. Kaiser
    A. Bernard
    N. Tran
    M. Acharya
    [J]. Cancer Chemotherapy and Pharmacology, 2013, 71 : 237 - 244
  • [44] Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine Yang
    Lim, Emerson A.
    Petrylak, Daniel Peter
    Peng, Weimin
    Maul, Raymond Scott
    Smit, Hans W.
    Tran, Namphuong
    Nanus, David M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer
    Chi, K. N.
    Tolcher, A.
    Lee, P.
    Rosen, P. J.
    Kollmannsberger, C. K.
    Papadopoulos, K. P.
    Patnaik, A.
    Molina, A.
    Jiao, J.
    Pankras, C.
    Kaiser, B.
    Bernard, A.
    Tran, N.
    Acharya, M.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 237 - 244
  • [46] A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Clayton, Ravinder
    Heng, Daniel Yick Chin
    Wu, Jackson S. Y.
    Zielinski, Rob
    North, Scott A.
    Emmenegger, Urban
    Hotte, Sebastien J.
    Al-Shamsi, Humaid Obaid
    Chen, Leo
    Eigl, Bernhard J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [47] The effects of enzalutamide (ENZA) in combination with abiraterone acetate (AA) in patients with bone metastatic castration resistant prostate cancer (mCRPC)
    Efstathiou, E.
    Titus, M.
    Wen, A. S.
    San Miguel, A.
    Hoang, A.
    De Haas-Amatsaleh, A.
    Perabo, F.
    Phung, D.
    Troncoso, P.
    Logothetis, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S680 - S681
  • [48] Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors
    Romero, Miguel E. jimenez
    Gallego, Maria Camacho
    Serrato, Jose c. navarro
    Sanchez Hurtado, Miguel A.
    Santotoribio, Jose D.
    [J]. ANTICANCER RESEARCH, 2021, 41 (08) : 3955 - 3968
  • [49] Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
    Azad, Arun
    Lester, Renee
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [50] Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.
    Posadas, Edwin M.
    Chi, Kim N.
    De Wit, Ronald
    De Jonge, Maja J.
    Attard, Gerhardt
    Friedlander, Terence W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345